endpts.com
Weight loss drugs were heralded as one of the biggest innovations in biopharma in 2023, as the GLP-1 contenders swelled into megablockbusters. But for one small biotech looking to make it big in the business of shedding pounds, this year marks the end of the line on a long and winding trail that led to biotech Boot Hill.
Gelesis, which was backed by PureTech, quietly filed for Chapter 7 bankruptcy liquidation mid-week, weeks after PureTech gave up on a plan to bring the s…
12 months ago